Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections

Stock Information for Beyond Air Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Beyond Air Inc.

Beyond Air to Participate in the 38th Annual Roth Conference in March
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.
Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences
Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast
Beyond Air Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.